Medicines for Malaria Venture (MMV)
@mmv.org
A leading global health partnership working to reduce the burden of malaria. We discover, develop and deliver new antimalarial medicines.
Is #malaria eradication still within reach?
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
November 26, 2025 at 12:53 PM
Is #malaria eradication still within reach?
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
@globalhealthedctp3.bsky.social builds and fosters Africa–Europe research partnerships transforming innovative science into global health impact, including the consortium behind Coartem Baby, the first #malaria treatment for infants 2 to <5 kg.
Read more: bit.ly/4ii8b7w
Read more: bit.ly/4ii8b7w
EDCTP: Two decades of Africa-Europe partnership delivering excellent science and life-saving innovations
Despite remarkable progress in global health, the world faces new threats, from re-emerging infections and pandemics to antimicrobial resistance and climate-related health impacts. Amid growing geopol...
bit.ly
November 26, 2025 at 11:12 AM
@globalhealthedctp3.bsky.social builds and fosters Africa–Europe research partnerships transforming innovative science into global health impact, including the consortium behind Coartem Baby, the first #malaria treatment for infants 2 to <5 kg.
Read more: bit.ly/4ii8b7w
Read more: bit.ly/4ii8b7w
Paul Boateng (Ghana NMEP) on staying ahead of antimalarial drug resistance, including the use of MFT to reduce pressure on ACTs. Through the ALARM partnership, MMV & Ghana's NMEP are conducting an MFT pilot following similar successful pilots in Kenya & Burkina Faso. #WAAW25
November 24, 2025 at 9:36 PM
Paul Boateng (Ghana NMEP) on staying ahead of antimalarial drug resistance, including the use of MFT to reduce pressure on ACTs. Through the ALARM partnership, MMV & Ghana's NMEP are conducting an MFT pilot following similar successful pilots in Kenya & Burkina Faso. #WAAW25
At #CPHIA2025, Dr Edwin Onyango from Kenya’s NMCP explained partial-artemisinin resistance.
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
November 24, 2025 at 4:21 PM
At #CPHIA2025, Dr Edwin Onyango from Kenya’s NMCP explained partial-artemisinin resistance.
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
How can collaboration, bold science & sustained funding help tackle antimalarial drug resistance?
MMV's Cristina Donini shares how resistance threatens the #malaria agenda & discusses our strategy to stay ahead of it.
Read more via Mediaplanet: bit.ly/4p9F9Jw
#WAAW25
MMV's Cristina Donini shares how resistance threatens the #malaria agenda & discusses our strategy to stay ahead of it.
Read more via Mediaplanet: bit.ly/4p9F9Jw
#WAAW25
A race against time: antimalarial drug resistance | Medicines for Malaria Venture
Cristina Donini, Head of Research and Early Development, MMV, shares her concerns around antimalarial drug resistance (AMDR) and outlines innovative strategies to advance malaria care and protect vuln...
bit.ly
November 24, 2025 at 4:15 PM
How can collaboration, bold science & sustained funding help tackle antimalarial drug resistance?
MMV's Cristina Donini shares how resistance threatens the #malaria agenda & discusses our strategy to stay ahead of it.
Read more via Mediaplanet: bit.ly/4p9F9Jw
#WAAW25
MMV's Cristina Donini shares how resistance threatens the #malaria agenda & discusses our strategy to stay ahead of it.
Read more via Mediaplanet: bit.ly/4p9F9Jw
#WAAW25
Drug resistance threatens #malaria elimination and global health security. Researchers across endemic countries, Japan and Europe are working together to develop new innovations and ensure communities can access effective, affordable tools.
More here: bit.ly/3X67ogi
More here: bit.ly/3X67ogi
Exploring New Frontiers In The Fight Against Malaria - Health Policy Watch
This week, the world marks World Antimicrobial Awareness Week and malaria parasites, though often forgotten, are part of the range of microbes preventing us
bit.ly
November 23, 2025 at 2:24 PM
Drug resistance threatens #malaria elimination and global health security. Researchers across endemic countries, Japan and Europe are working together to develop new innovations and ensure communities can access effective, affordable tools.
More here: bit.ly/3X67ogi
More here: bit.ly/3X67ogi
In case you missed it: last week, @novartis.bsky.social & MMV announced positive Phase 3 results for GanLum, a novel, non-artemisinin antimalarial. This milestone comes amid urgent calls to tackle emerging drug resistance. Read more in @npr.org: bit.ly/4oTKuVx
New malaria drug could be a life-saver as the standard drug shows signs of weakness
The best drug to fight malaria is facing increased resistance from the parasites it fights. Now there's an alternative in the pipeline and it looks promising.
bit.ly
November 21, 2025 at 9:11 PM
In case you missed it: last week, @novartis.bsky.social & MMV announced positive Phase 3 results for GanLum, a novel, non-artemisinin antimalarial. This milestone comes amid urgent calls to tackle emerging drug resistance. Read more in @npr.org: bit.ly/4oTKuVx
Parasites developing resistance to #malaria mediciness isn’t a question of if, but when. We must act now to protect gains & secure a malaria-free future.
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
November 21, 2025 at 7:04 PM
Parasites developing resistance to #malaria mediciness isn’t a question of if, but when. We must act now to protect gains & secure a malaria-free future.
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
Press release: @who.int has prequalified the first-ever paediatric formulations of primaquine, paving the way for improved access to critical treatment for children in malaria-endemic regions 👉 bit.ly/43DdY1r
WHO approves first child-friendly primaquine formulations for malaria treatment | Medicines for Malaria Venture
bit.ly
November 20, 2025 at 9:44 PM
Press release: @who.int has prequalified the first-ever paediatric formulations of primaquine, paving the way for improved access to critical treatment for children in malaria-endemic regions 👉 bit.ly/43DdY1r
As #COP30 begins, the link between #climatechange & health is more urgent than ever & a major leadership opportunity. Read an op-ed published in @Devex on long-lasting, single-dose tools that could transform #malaria protection in unpredictable climate: bit.ly/4i6vhhe
Innovation meets impact: Fighting malaria in a warming world
Opinion: As climate pressures reshape malaria transmission, long-lasting, single-dose tools have the potential to provide protection suited to increasingly unpredictable settings.
bit.ly
November 20, 2025 at 2:56 PM
As #COP30 begins, the link between #climatechange & health is more urgent than ever & a major leadership opportunity. Read an op-ed published in @Devex on long-lasting, single-dose tools that could transform #malaria protection in unpredictable climate: bit.ly/4i6vhhe
For the first time in 25 years, a new class of #malaria treatment is within reach. Today, @Novartis & MMV announce positive Phase 3 results for a novel, non-artemisinin medicine with the potential to kill drug-resistant parasites & block transmission. bit.ly/4p78R1P
November 13, 2025 at 7:26 AM
For the first time in 25 years, a new class of #malaria treatment is within reach. Today, @Novartis & MMV announce positive Phase 3 results for a novel, non-artemisinin medicine with the potential to kill drug-resistant parasites & block transmission. bit.ly/4p78R1P
This week at #ASTMH25, the Partnership for Vivax Elimination (PAVE) network came together to show what’s possible when evidence, partnerships and policy align to turn innovative tools and collaborative research into real-world impact.
November 12, 2025 at 10:16 PM
This week at #ASTMH25, the Partnership for Vivax Elimination (PAVE) network came together to show what’s possible when evidence, partnerships and policy align to turn innovative tools and collaborative research into real-world impact.
We are the impatient optimists who believe in #malaria eradication in our lifetime. Today at #ASTMH25, MMV & @gatesfoundation.bsky.social convened leading global health experts for a special symposium to reaffirm their shared belief in a malaria-free future. Stay tuned for the video.
November 12, 2025 at 6:23 PM
We are the impatient optimists who believe in #malaria eradication in our lifetime. Today at #ASTMH25, MMV & @gatesfoundation.bsky.social convened leading global health experts for a special symposium to reaffirm their shared belief in a malaria-free future. Stay tuned for the video.
MMV is at #ASTMH25!
Meet us in the exhibition hall at booth (512) – come for the Swiss chocolate and Italian coffee, stay for chats about our work & partnerships advancing the #malaria elimination agenda.
See all our activities at #TropMed25 this week 👉bit.ly/4hSZTmC
Meet us in the exhibition hall at booth (512) – come for the Swiss chocolate and Italian coffee, stay for chats about our work & partnerships advancing the #malaria elimination agenda.
See all our activities at #TropMed25 this week 👉bit.ly/4hSZTmC
November 10, 2025 at 5:13 PM
MMV is at #ASTMH25!
Meet us in the exhibition hall at booth (512) – come for the Swiss chocolate and Italian coffee, stay for chats about our work & partnerships advancing the #malaria elimination agenda.
See all our activities at #TropMed25 this week 👉bit.ly/4hSZTmC
Meet us in the exhibition hall at booth (512) – come for the Swiss chocolate and Italian coffee, stay for chats about our work & partnerships advancing the #malaria elimination agenda.
See all our activities at #TropMed25 this week 👉bit.ly/4hSZTmC
Heading to #ASTMH2025 in Toronto? 🇨🇦
MMV will be on hand in the exhibition hall (booth 512) & throughout the week, sharing research via scientific symposia & poster/oral presentation sessions. Explore MMV & partner activities at the ASTMH Annual Meeting: bit.ly/4hSZTmC
MMV will be on hand in the exhibition hall (booth 512) & throughout the week, sharing research via scientific symposia & poster/oral presentation sessions. Explore MMV & partner activities at the ASTMH Annual Meeting: bit.ly/4hSZTmC
November 7, 2025 at 10:40 AM
Heading to #ASTMH2025 in Toronto? 🇨🇦
MMV will be on hand in the exhibition hall (booth 512) & throughout the week, sharing research via scientific symposia & poster/oral presentation sessions. Explore MMV & partner activities at the ASTMH Annual Meeting: bit.ly/4hSZTmC
MMV will be on hand in the exhibition hall (booth 512) & throughout the week, sharing research via scientific symposia & poster/oral presentation sessions. Explore MMV & partner activities at the ASTMH Annual Meeting: bit.ly/4hSZTmC
MMV staff are celebrating #MalariaDayInTheAmericas by joining the Brazilian #MedTrop25 Conference in Belém this week!
November 6, 2025 at 8:06 PM
MMV staff are celebrating #MalariaDayInTheAmericas by joining the Brazilian #MedTrop25 Conference in Belém this week!
Symposium: MMV & partners at #ASTMH2025
📅 10 Nov: Evidence to guide the implementation of effective P. vivax radical cure
Lessons from Brazil, Peru, PNG & Indonesia on optimizing radical cure for vivax #malaria relapse prevention
Speakers & topics 👉 bit.ly/3KVqVx7
📅 10 Nov: Evidence to guide the implementation of effective P. vivax radical cure
Lessons from Brazil, Peru, PNG & Indonesia on optimizing radical cure for vivax #malaria relapse prevention
Speakers & topics 👉 bit.ly/3KVqVx7
November 3, 2025 at 6:08 PM
Symposium: MMV & partners at #ASTMH2025
📅 10 Nov: Evidence to guide the implementation of effective P. vivax radical cure
Lessons from Brazil, Peru, PNG & Indonesia on optimizing radical cure for vivax #malaria relapse prevention
Speakers & topics 👉 bit.ly/3KVqVx7
📅 10 Nov: Evidence to guide the implementation of effective P. vivax radical cure
Lessons from Brazil, Peru, PNG & Indonesia on optimizing radical cure for vivax #malaria relapse prevention
Speakers & topics 👉 bit.ly/3KVqVx7
📣 Applications are open!
The SAHRI Fellowship (2026–2029), funded by @globalhealthedctp3.bsky.social, supports mid-career scientists in sub-Saharan Africa advancing health research & innovation in infectious diseases.
Apply now 👉 bit.ly/4qfTdT6
The SAHRI Fellowship (2026–2029), funded by @globalhealthedctp3.bsky.social, supports mid-career scientists in sub-Saharan Africa advancing health research & innovation in infectious diseases.
Apply now 👉 bit.ly/4qfTdT6
ITM project: SAHRI Fellowship programme
The SAHRI Fellowship programme empowers a new generation of researchers to address critical gaps in health research & innovation in sub-Saharan Africa
bit.ly
October 31, 2025 at 9:57 AM
📣 Applications are open!
The SAHRI Fellowship (2026–2029), funded by @globalhealthedctp3.bsky.social, supports mid-career scientists in sub-Saharan Africa advancing health research & innovation in infectious diseases.
Apply now 👉 bit.ly/4qfTdT6
The SAHRI Fellowship (2026–2029), funded by @globalhealthedctp3.bsky.social, supports mid-career scientists in sub-Saharan Africa advancing health research & innovation in infectious diseases.
Apply now 👉 bit.ly/4qfTdT6
MMV & Chiang Mai University have launched a qualitative study in Thailand on paediatric formulations of primaquine and tafenoquine for P. vivax #malaria relapse prevention, exploring perceptions around their use with G6PD testing.
October 30, 2025 at 11:12 AM
MMV & Chiang Mai University have launched a qualitative study in Thailand on paediatric formulations of primaquine and tafenoquine for P. vivax #malaria relapse prevention, exploring perceptions around their use with G6PD testing.
Malaria can become deadly within hours. Through SEMA ReACT, MMV & partners are studying rectal artesunate use in remote Zambia & DRC to improve severe #malaria care. Join us at #ASTMH2025 (11 Nov) for a symposium sharing interim results & insights 👉 bit.ly/46Z7ADQ
October 29, 2025 at 3:37 PM
Malaria can become deadly within hours. Through SEMA ReACT, MMV & partners are studying rectal artesunate use in remote Zambia & DRC to improve severe #malaria care. Join us at #ASTMH2025 (11 Nov) for a symposium sharing interim results & insights 👉 bit.ly/46Z7ADQ
Diversifying the use of #malaria meds through the deployment of MFT can keep us one step ahead of resistance. MMV & partners recently conducted a feasibility study in Kenya demonstrating that an MFT approach is feasible, with adequate resources 👉 bit.ly/3IVeQYh
October 29, 2025 at 1:54 PM
Diversifying the use of #malaria meds through the deployment of MFT can keep us one step ahead of resistance. MMV & partners recently conducted a feasibility study in Kenya demonstrating that an MFT approach is feasible, with adequate resources 👉 bit.ly/3IVeQYh
Are you subscribed to MMV’s monthly newsletter?
Get the latest news on MMV projects, partnerships & initiatives advancing the global #malaria elimination agenda, as well as info on events, scientific publications & job opportunities within MMV
👉 bit.ly/MMVnewsletter
Get the latest news on MMV projects, partnerships & initiatives advancing the global #malaria elimination agenda, as well as info on events, scientific publications & job opportunities within MMV
👉 bit.ly/MMVnewsletter
October 28, 2025 at 8:36 AM
Are you subscribed to MMV’s monthly newsletter?
Get the latest news on MMV projects, partnerships & initiatives advancing the global #malaria elimination agenda, as well as info on events, scientific publications & job opportunities within MMV
👉 bit.ly/MMVnewsletter
Get the latest news on MMV projects, partnerships & initiatives advancing the global #malaria elimination agenda, as well as info on events, scientific publications & job opportunities within MMV
👉 bit.ly/MMVnewsletter
MMV joins the global health community in mourning the passing of our friend & colleague, Prof. Jean Louis Abdourahim Ndiaye.
As we honour Prof. Ndiaye’s memory, we extend our deepest condolences to his family, close friends & colleagues around the world: shorturl.at/VSzLG
As we honour Prof. Ndiaye’s memory, we extend our deepest condolences to his family, close friends & colleagues around the world: shorturl.at/VSzLG
In memory of Professor Jean Louis Abdourahim Ndiaye | Medicines for Malaria Venture
shorturl.at
October 27, 2025 at 1:45 PM
MMV joins the global health community in mourning the passing of our friend & colleague, Prof. Jean Louis Abdourahim Ndiaye.
As we honour Prof. Ndiaye’s memory, we extend our deepest condolences to his family, close friends & colleagues around the world: shorturl.at/VSzLG
As we honour Prof. Ndiaye’s memory, we extend our deepest condolences to his family, close friends & colleagues around the world: shorturl.at/VSzLG
“Innovation can’t wait; we need to act now,” says MMV CEO Martin Fitchet, in an opinion piece on the urgent need to stop #malaria drug resistance in its tracks. Read it in @devex.com
👉 bit.ly/42UQ8xU
👉 bit.ly/42UQ8xU
October 23, 2025 at 8:00 AM
“Innovation can’t wait; we need to act now,” says MMV CEO Martin Fitchet, in an opinion piece on the urgent need to stop #malaria drug resistance in its tracks. Read it in @devex.com
👉 bit.ly/42UQ8xU
👉 bit.ly/42UQ8xU